IMODIUM MULTI-SYMPTOM RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMODIUM MULTI-SYMPTOM RELIEF (IMODIUM MULTI-SYMPTOM RELIEF).
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, thereby allowing for greater absorption of water and electrolytes. Simethicone reduces surface tension of gas bubbles, facilitating their coalescence and expulsion.
| Metabolism | Loperamide is extensively metabolized by CYP2C8 and CYP3A4, with minor contributions from CYP2D6. Simethicone is not absorbed and is excreted unchanged in feces. |
| Excretion | Fecal: ~60% (loperamide and metabolites); Renal: ~1-2% (unchanged loperamide and glucuronide conjugates); Biliary: minimal, as loperamide undergoes extensive enterohepatic recirculation. |
| Half-life | Terminal elimination half-life is approximately 9-14 hours (mean 11 hours) in plasma; in clinical context, it supports twice-daily dosing for chronic diarrhea. |
| Protein binding | ~97% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.5-3.0 L/kg; high Vd indicates extensive tissue distribution beyond the central compartment, consistent with peripheral opiate receptor binding. |
| Bioavailability | Oral: ~0.3-0.5% (low due to extensive first-pass metabolism); rectally: ~50% (bypasses first-pass effect to some extent). |
| Onset of Action | Oral: ~4-6 hours for full antidiarrheal effect; however, initial slowing of gastrointestinal motility begins within 1-3 hours after a single dose. |
| Duration of Action | Up to 12-24 hours after a single oral dose; clinical notes: duration may be prolonged in patients with hepatic impairment (due to reduced first-pass metabolism) or in cases of overdose. |
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription up to 16 mg/day). Route: oral.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: use with caution; consider dose reduction due to reduced first-pass metabolism and increased systemic exposure. |
| Pediatric use | Children 6–11 years: 2 mg initially, then 1 mg after each unformed stool; maximum 6 mg/day. Children 12–17 years: same as adult dosing. Weight-based: not required; age-based dosing is standard. |
| Geriatric use | No specific dose adjustment; monitor for constipation and central nervous system effects due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IMODIUM MULTI-SYMPTOM RELIEF (IMODIUM MULTI-SYMPTOM RELIEF).
| Breastfeeding | Loperamide is excreted in breast milk at low levels; M/P ratio approximately 0.73. Use caution, especially in infants with pre-existing conditions. |
| Teratogenic Risk | Limited human data; animal studies show no teratogenic risk at therapeutic doses. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor for maternal constipation, abdominal pain, and signs of ileus. Fetal assessment per standard obstetric care. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to loperamide or simethicone, children under 6 years of age, acute dysentery characterized by bloody stools and high fever, acute ulcerative colitis, pseudomembranous colitis, bacterial enterocolitis, intestinal obstruction, and constipation.
| Precautions | Avoid use in patients with bloody diarrhea, high fever, or suspected bacterial enterocolitis. Do not use if diarrhea is accompanied by mucus or if abdominal pain is severe. Discontinue if no improvement within 48 hours. Risk of QT prolongation and torsades de pointes at high doses. Use with caution in hepatic impairment. |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility in animal studies; human data lacking. |